Synthesis, cytotoxic evaluation, and molecular docking of novel triazolopyridazine-pyrazole derivatives as potential anticancer agents
摘要
Breast cancer remains a leading cause of cancer mortality, demanding new chemotherapeutic options. A novel series of triazolopyridazine-pyrazole derivatives (11a-h) was synthesized and evaluated for cytotoxicity against MCF-7 breast cancer cells. Sulforhodamine B assay results identified compound 11e as the only active derivative, exhibiting moderate inhibition with a GI50 of 52 µg/mL, while all others were inactive (GI50 > 80 µg/mL). Molecular docking provided mechanistic support, revealing that 11e had the highest affinity for EGFR (PDB ID: 1M17; ˗10.1 kcal/mol, H-bond with MET769), along with strong interactions with Bcl-2 (2W3L; ˗9.9 kcal/mol) and p73 (2WTT; ˗9.5 kcal/mol). These findings suggest that 11e may exert anticancer effects via multi-target modulation, positioning it as a promising scaffold for further optimization.
Graphical abstract